Aurobindo pharma Limited has secured a significant regulatory milestone with the US Food & Drug Administration (USFDA) granting final approval for its generic diabetes medication. The approval, announced on April 07, 2026, covers Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in multiple strengths, positioning the company to capture a substantial share of the US diabetes treatment market.

Regulatory Approval Details

The USFDA has approved four different strengths of the diabetes medication, demonstrating the comprehensive nature of Aurobindo Pharma's application. The approved formulations are bioequivalent and therapeutically equivalent to AstraZeneca AB's reference listed drug, Xigduo XR Tablets.

Market Opportunity and Exclusivity Benefits

The approved product represents a significant commercial opportunity for Aurobindo Pharma, with substantial market potential in the competitive US pharmaceutical landscape. The company's strategic positioning as an early applicant has secured valuable market advantages.

As one of the first ANDA applicants to submit a substantially complete application with paragraph IV certification, Aurobindo Pharma has earned the right to 180 days of shared generic drug exclusivity. This exclusivity period provides a competitive advantage by limiting the number of generic competitors in the initial launch phase.

Manufacturing and Portfolio Expansion

The products will be manufactured at Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of Aurobindo Pharma. This approval adds to the company's extensive portfolio of USFDA-approved products, reinforcing its position in the US generics market.

As of March 31, 2026, Aurobindo Pharma holds a total of 579 ANDA approvals from the USFDA, comprising 554 final approvals and 25 tentative approvals. This latest approval strengthens the company's presence in the anti-diabetic therapeutic segment.

Therapeutic Application

Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes mellitus. The medication is prescribed when treatment with both dapagliflozin and metformin is clinically appropriate, addressing the growing need for combination therapies in diabetes management.

The immediate launch of these products positions Aurobindo Pharma to serve the substantial US market for type-2 diabetes treatments, leveraging both the market opportunity and the temporary competitive advantage provided by the exclusivity period.

Aurobindo Pharma 's wholly-owned subsidiary CuraTeQ Biologics has announced positive top-line results from its Phase 3 study of BP11, an investigational biosimilar to Xolair (omalizumab). The comprehensive trial successfully met all primary endpoints, demonstrating high comparability to the reference product in patients with chronic spontaneous urticaria at the 300 mg dose.

Clinical Trial Results

The Phase 3 trial was conducted across 608 patients at approximately 80 sites in seven European countries and India. The study evaluated change from baseline in ISS7 (7-point Itch Severity Score) at Week 12, serving as the main primary endpoint applicable for both FDA and EMA approvals.

Results demonstrated precise equivalence with tight confidence intervals well within the predefined margins of -2.50 to 2.00. The co-primary endpoint of relative potency, based on change from baseline in ISS7 at Week 12 using a 4-point assay, also met its criteria, demonstrating parallelism between BP11 and Xolair across dose levels.

Regulatory Strategy and Timeline

Following the successful Phase 3 results, CuraTeQ Biologics has outlined its regulatory filing timeline. The company plans to complete submissions to both major regulatory authorities by the end of Q2 2026.

The results support regulatory submissions targeting chronic spontaneous urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP).

Management Commentary

Dr. Arpitkumar Prajapati, Head of Clinical Development, stated that the Phase 3 results with narrow confidence intervals validate the clinical strategy and team execution in delivering a high-quality biosimilar. He noted that detailed results will be submitted for regulatory review and presented at upcoming medical conferences.

Dr. Disha Dadke, Head of R&D and Regulatory Sciences, emphasized that BP11 demonstrates comparable efficacy and safety to Xolair, paving the way for patient access to affordable treatment options.

Market Impact

The successful Phase 3 results position BP11 as a potential competitor in the omalizumab biosimilar market. The outcomes reflect well-contained variability, robustness of data, and strong efficacy alignment with the reference product. Omalizumab is a monoclonal antibody used primarily for treating severe allergic asthma and chronic idiopathic urticaria, representing a significant therapeutic market opportunity for biosimilar alternatives.